INTERIM RESULTS OF A PHASE II STUDY OF FONDAZIONE ITALIANA LINFOMI ON GEMCITABINE PLUS ROMIDEPSIN IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA PATIENTS

被引：0
|
作者：
Pellegrini, C. [1 ]
Broccoli, A. [1 ]
Casadei, B. [1 ]
Chiappella, A. [2 ]
Corradini, P. [3 ]
Derenzini, E. [1 ]
Dodero, A. [3 ]
Farina, L. [3 ]
Gandolfi, L. [1 ]
Ladetto, M. [4 ]
Monaco, F. [4 ]
Orsucci, L. [2 ]
Quirini, F. [1 ]
Salvi, F. [4 ]
Spina, F. [3 ]
Stefoni, V. [1 ]
Tonialini, L. [1 ]
Vitolo, U. [2 ]
Argnani, L. [1 ]
Cavo, M. [1 ]
Zinzani, P. L. [1 ]
机构：
[1] Univ Bologna, Inst Hematol L & A Seragnoli, Bologna, Italy
[2] Azienda Osped Univ Citta Salute & Sci Torino, Hematol, Turin, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Hematol, Milan, Italy
[4] SS Antonio & Biagio Hosp Alessandria, Hematol, Alessandria, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C029
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [41] Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
    Ruan, Jia
    Zain, Jasmine M.
    Palmer, Brett
    Jovanovic, Borko
    Mi, Xinlei
    Swaroop, Alok
    Winter, Jane
    Gordon, Leo I.
    Karmali, Reem
    Pro, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
    Agbedia, Owhofasa O.
    Prakash, Rishab
    Xu, Jie
    Becnel, Melody R.
    Nair, Ranjit
    Steiner, Raphael E.
    Feng, Lei
    Lee, Hun Ju
    Strati, Paolo
    Ahmed, Sairah
    Parmar, Simrit
    Nieto, Yago
    Hosing, Chitra
    Westin, Jason
    Nastoupil, Loretta J.
    Ann Vo
    Samaniego, Felipe
    Fowler, Nathan H.
    Saini, Neeraj
    Khouri, Issa F.
    Im, Jin S.
    Fayad, Luis
    Jain, Preetesh
    Wang, Michael L.
    Miranda, Roberto N.
    Vega, Francisco
    Medeiros, Jeffrey
    Oki, Yasuhiro
    Flowers, Christopher R.
    Neelapu, Sattva S.
    Iyer, Swaminathan P.
    BLOOD, 2022, 140 : 2313 - 2315
  • [43] PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/ REFRACTORY PERIPHERAL T-CELL LYMPHOMA
    Suzuki, R.
    Hyo, R.
    Kim, W. S.
    Tsukamoto, N.
    Maeda, Y.
    Masaki, Y.
    Sakai, R.
    Masunari, T.
    Niitsu, N.
    Ishida, F.
    Nakamura, S.
    Suzumiya, J.
    HAEMATOLOGICA, 2015, 100 : 401 - 401
  • [44] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    O'Connor, O.
    Pro, B.
    Pinter-Brown, L.
    Popplewell, L.
    Bartlett, N.
    Lechowicz, M.
    Savage, K.
    Coiffier, B.
    Saunders, M.
    Horwitz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
    Brammer, Jonathan E.
    Zinzani, Pier Luigi
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Jacobsen, Eric D.
    Gritti, Giuseppe
    Litwak, Debra
    Cohan, David
    Katz, Danica J.
    Mehta-Shah, Neha
    Pro, Barbara
    Horwitz, Steven M.
    BLOOD, 2021, 138
  • [46] Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
    Arcari, Annalisa
    Morello, Lucia
    Vallisa, Daniele
    Marcheselli, Luigi
    Tecchio, Cristina
    Quaglia, Francesca Maria
    Tisi, Maria Chiara
    Zilioli, Vittorio Ruggero
    Di Rocco, Alice
    Perrone, Tommasina
    Gini, Guido
    Dogliotti, Irene
    Bianchetti, Nicola
    Bozzoli, Valentina
    De Philippis, Chiara
    De Celis, Maria Isabel Alvarez
    Chiappella, Annalisa
    Fabbri, Alberto
    Pelosini, Matteo
    Merli, Michele
    Molinari, Anna Lia
    Sciarra, Roberta
    Volpetti, Stefano
    Hohaus, Stefan
    Nassi, Luca
    Visco, Carlo
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3474 - 3483
  • [47] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [48] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
  • [49] RITUXIMAB, BENDAMUSTINE AND CYTARABINE AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI
    Visco, C.
    Chiappella, A.
    Franceschetti, S.
    Patti, C.
    Ferrero, S.
    Barbero, D.
    Evangelista, A.
    Spina, M.
    Molinari, A.
    Rigacci, L.
    Tani, M.
    Di Rocco, A.
    Pinotti, G.
    Fabbri, A.
    Zambello, R.
    Finotto, S.
    Gotti, M.
    Carella, A. M.
    Salvi, F.
    Pileri, S. A.
    Ladetto, M.
    Zaja, F.
    Gaidano, G.
    Vitolo, U.
    Rodeghiero, F.
    HAEMATOLOGICA, 2015, 100 : 4 - 4
  • [50] A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Yang, Haiyan
    Li, Zhiming
    Bao, Hanying
    Xu, Zusheng
    Qiu, Lugui
    Shu, Yang
    Li, Fei
    Wang, Zhen
    BLOOD, 2021, 138
12345